The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support. Pharma-Bio Serv operates in Puerto Rico, the United States, Europe, Brazil, and internationally.
Cyborg Score Rationale
The company has a market capitalization of approximately $12.3M as of June 2026, indicating a micro-cap footprint. While the company has a diversified service offering and geographic presence, the small valuation and OTC trading status reflect limited investor confidence and liquidity constraints.
Top Insights
The company operates a laboratory testing facility in Puerto Rico offering microbiological and chemical testing services
Pharma-Bio Serv offers a notably high dividend yield of 13.95%, suggesting a mature, low-growth profile
Founded in 1993, the company has operated for over 30 years
Highly concentrated geographic revenue dependence with significant Puerto Rico exposure may limit scalability
Named Competitors
Regulatory Consulting Services — Global life sciences consulting and clinical research organization
Compliance & Quality Services — Laboratory and consulting services for pharmaceutical and biotech
Technology Transfer Services — Preclinical and clinical laboratory services for drug development
Recent Developments
(January 2025) Released full-year earnings results and declared dividend
(March 2025) Announced return to growth trajectory
(June 2025) Reported positive business decisions and continued positive performance
Open the full interactive Pharma-Bio Serv, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.